composite

Biotech Tools & CRO Core

members 5 weighting equal benchmark SPY

Equal-weight composite of the tools/CRO tier of the biotech capital-cycle thesis: quality laggards that monetize a reopened biotech funding window without single-trial risk — instruments (TMO, DHR), contract research (MEDP), bioprocessing (RGEN), and computational chemistry (SDGR).

Cumulative return since Sep 8 — both lines start at 0%, so the gap between them IS the out/under-performance. Hover for daily values.

	1D	7D	30D	3M	1Y
cohort	+2.6%	-1.8%	+13.6%	+27.0%	+19.5%
SPY	+0.6%	+1.2%	+2.1%	+3.1%	+16.0%
Δ	+2.0%	-3.0%	+11.4%	+23.9%	+3.5%

equal-weight · buy-and-hold from window start, no rebalancing · 3M+ windows are a current-roster backcast.

30D breadth 5/5 up

trend: 5 up · 0 flat · 0 down · avg RSI 52 · 100% above SMA200 · covered 5/5

contributors

SDGR+8.4pp+42.1%

TMO+1.7pp+8.6%

DHR+1.5pp+7.3%

RGEN+1.1pp+5.3%

MEDP+0.9pp+4.4%

SDGR $27.28 +3.4% +42.1% +65.4% +32.1% 52 coming into play -19.2%

TMO $658.02 +0.9% +8.6% +24.9% +23.1% 54 in trend -5.2%

DHR $219.81 +1.1% +7.3% +10.4% +7.5% 55 in trend -9.5%

RGEN $173.88 +6.1% +5.3% +20.6% +16.9% 48 coming into play -12.6%

MEDP $612.05 +1.6% +4.4% +13.7% +18.0% 52 in trend -9.7%